ArticleScientific reports2026
Epstein-Barr virus-specific T-cells in pediatric liver transplant recipients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine Epstein-Barr virus (EBV)-specific T-cell responses after pediatric liver transplantation (LT), we monitored EBV viral load and IFNγ-producing specific T-cells reacting to BZLF1, EBNA1, and LMP2 antigens from peripheral immune cells before LT until 48 weeks after LT. Among forty children, seven (17.5%) developed EBV infection. Two were subsequently diagnosed with post-transplant lymphoproliferative disorders. The infected children exhibited fewer EBNA1-specific CD4 + T-cells and CD8 + T-cells before LT (P = 0.01 and P = 0.02, respectively) than non-infected children. At 32 weeks after LT, EBNA1-specific CD4 + T-cells, LMP2-specific CD4 + T-cells, and BZLF1-specific CD8 + T-cells were lower in the infected children (P = 0.02, P < 0.01, and P = 0.02, respectively). EBV infection-free survival rates (IFSR) were higher in groups with detected EBNA1-specific CD4 + or CD8 + T-cells prior to LT compared to non-detected group. No patients with detected EBNA1-specific CD8 + T-cells reported EBV infection after LT (a 48-week IFSR of 100%). However, the differences of IFSR were statistically insignificant (HR 0.25; 95% CI 0.05 to 1.3, and HR 0.42; 95% CI 0.09 to 1.86, respectively). LMP2-specific CD4 + T-cells were negatively correlated with EBV viral load (r = - 0.702, P = 0.02). In conclusion, EBV infection after pediatric LT is associated with lower expression of EBV-specific T-cells, which may be potential predictors for the infection after LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.